penicillamine has been researched along with Scleroderma, Diffuse in 8 studies
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.
penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.
Scleroderma, Diffuse: A rapid onset form of SYSTEMIC SCLERODERMA with progressive widespread SKIN thickening over the arms, the legs and the trunk, resulting in stiffness and disability.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eighty-four patients with diffuse cutaneous systemic sclerosis who had received D-penicillamine within 24 months of clinically detectable onset of skin sclerosis were randomly selected from the systemic sclerosis cohort followed at the Scleroderma Center of Thomas Jefferson University." | 7.74 | A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. ( Derk, CT; Huaman, G; Jimenez, SA, 2008) |
| "In patients presenting with early diffuse scleroderma prognosis is variable." | 3.81 | The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. ( Clements, PJ; Pope, JE; Sultan, N, 2004) |
| "Eighty-four patients with diffuse cutaneous systemic sclerosis who had received D-penicillamine within 24 months of clinically detectable onset of skin sclerosis were randomly selected from the systemic sclerosis cohort followed at the Scleroderma Center of Thomas Jefferson University." | 3.74 | A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. ( Derk, CT; Huaman, G; Jimenez, SA, 2008) |
| "Stiff skin syndrome is a sclerodermalike disorder that presents in infancy or early childhood with rock-hard skin, limited joint mobility, and mild hypertrichosis in the absence of visceral or muscle involvement, immunologic abnormalities, or vascular hyperreactivity." | 2.44 | The stiff skin syndrome: case series, differential diagnosis of the stiff skin phenotype, and review of the literature. ( Connolly, MK; Frieden, IJ; Gilliam, AE; Liu, T; McCalmont, TH; Williams, ML, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, T | 1 |
| McCalmont, TH | 1 |
| Frieden, IJ | 1 |
| Williams, ML | 1 |
| Connolly, MK | 1 |
| Gilliam, AE | 1 |
| Tseng, CH | 1 |
| Wong, WK | 3 |
| Le, EN | 1 |
| Wigley, FM | 1 |
| Shah, AA | 1 |
| Boin, F | 1 |
| Hummers, LK | 1 |
| Sultan, N | 1 |
| Pope, JE | 1 |
| Clements, PJ | 3 |
| Santiago, M | 1 |
| de Castro, DO | 1 |
| Costa, CA | 1 |
| Passos, ES | 1 |
| Paixão, A | 1 |
| Khanna, D | 1 |
| Furst, DE | 2 |
| Hays, RD | 1 |
| Park, GS | 1 |
| Seibold, JR | 1 |
| Mayes, MD | 1 |
| White, B | 1 |
| Wigley, FF | 1 |
| Weisman, M | 1 |
| Barr, W | 1 |
| Moreland, L | 1 |
| Medsger, TA | 1 |
| Steen, VD | 1 |
| Martin, RW | 1 |
| Collier, D | 1 |
| Weinstein, A | 1 |
| Lally, EV | 1 |
| Varga, J | 1 |
| Weiner, SR | 1 |
| Andrews, B | 1 |
| Abeles, M | 1 |
| Streisand, JB | 1 |
| Derk, CT | 1 |
| Huaman, G | 1 |
| Jimenez, SA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Physical Rehabilitation in Women With Scleroderma: Effects on Pulmonary Function, Lung Ultrasound, Muscle Function, Hand Functional, Functional Capacity, and Quality of Life[NCT05041868] | 104 participants (Anticipated) | Interventional | 2021-10-15 | Recruiting | |||
| A Phase II, Double-blind, Randomized, Placebo-controlled Study to Investigate Pharmacokinetics (PK), Safety and Efficacy of Intravenous Factor XIII Treatment in Patients With Systemic Sclerosis[NCT02551042] | Phase 2 | 26 participants (Anticipated) | Interventional | 2015-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for penicillamine and Scleroderma, Diffuse
| Article | Year |
|---|---|
The stiff skin syndrome: case series, differential diagnosis of the stiff skin phenotype, and review of the literature.
Topics: Age Distribution; Biopsy, Needle; Child; Child, Preschool; Disease Progression; Fascia; Female; Huma | 2008 |
Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.
Topics: Adult; Collagen Type I; Epidemiologic Methods; Female; Humans; Immunosuppressive Agents; Male; Middl | 2011 |
The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
Topics: Dermatologic Agents; Disability Evaluation; Female; Health Status Indicators; Humans; Immunosuppress | 2004 |
2 trials available for penicillamine and Scleroderma, Diffuse
| Article | Year |
|---|---|
The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
Topics: Dermatologic Agents; Disability Evaluation; Female; Health Status Indicators; Humans; Immunosuppress | 2004 |
Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.
Topics: Adult; Antirheumatic Agents; Disability Evaluation; Dose-Response Relationship, Drug; Female; Follow | 2006 |
4 other studies available for penicillamine and Scleroderma, Diffuse
| Article | Year |
|---|---|
Analysis of a composite endpoint with longitudinal and time-to-event data.
Topics: Computer Simulation; Data Interpretation, Statistical; Humans; Longitudinal Studies; Penicillamine; | 2011 |
Keloidal scleroderma.
Topics: Adult; Antirheumatic Agents; Azathioprine; Female; Humans; Keloid; Penicillamine; Scleroderma, Diffu | 2004 |
Assessing disease progression using a composite endpoint.
Topics: Antirheumatic Agents; Data Interpretation, Statistical; Disease Progression; Endpoint Determination; | 2007 |
A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset.
Topics: Antirheumatic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle | 2008 |